RGNX vs SLDB
RGNX: A clinical-stage gene therapy developer leveraging its proprietary AAV platform to create potentially curative, one-time treatments for serious genetic diseases. SLDB: A clinical-stage biotechnology company developing gene therapies to treat rare, life-threatening neuromuscular and cardiac diseases.
Side-by-side fundamentals
| Metric | RGNX | SLDB | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $8.09 | $6.82 | |
| Market cap | $534M | $731M | |
| Net margin | -113.8% | -1062.3% | RGNX higher |
| Operating margin | -94.6% | -1315.2% | RGNX higher |
| ROE FY2025, SEC XBRL | -188.7% | -96.8% | SLDB higher |
| ROA FY2025, SEC XBRL | -42.8% | -75.0% | RGNX higher |
| Debt / equity as of 2026-09-02 | 2.53 | 0.00 | SLDB lower |
| Revenue growth (YoY) as of 2026-09-02 | +12.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.88 | 1.68 | |
| 1-year return as of 2026-10-08 close | -33.8% | +8.1% | SLDB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.